Samsung Bioepis has announced the initiation of phase-I clinical trial for SBE303.

SBE303 is Samsung Bioepis’s first novel Antibody-Drug Conjugate (ADC) candidate engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer.

The phase-I clinical trial for SBE303 is an open?label, multi-center, first?in?human trial to evaluate the safety, tolerability and efficacy of SBE303 in participants with advanced refractory solid tumors.

“We are thrilled to announce the initiation of our first-in-human phase-I clinical trial of our first novel Antibody-Drug Conjugate (ADC) candidate,” the company said in a statement.